Yksityiskohtainen opas tulossa pian
Työskentelemme kattavan oppaan parissa kohteelle Epworth Sleepiness Scale. Palaa pian katsomaan vaiheittaiset selitykset, kaavat, käytännön esimerkit ja asiantuntijavinkit.
The Epworth Sleepiness Scale (ESS) is a validated, self-administered questionnaire developed by Dr Murray Johns at the Epworth Hospital in Melbourne, Australia, and first published in 1991. It is the most widely used tool for measuring daytime sleepiness in clinical practice and research worldwide. Unlike subjective global sleepiness ratings, the ESS asks respondents to rate their likelihood of dozing or falling asleep in eight specific real-world situations — capturing habitual somnolence rather than momentary fatigue. The eight situations assessed span a range from highly somnolent (e.g., lying down to rest in the afternoon when circumstances permit) to least somnolent (e.g., sitting and reading). Each situation is rated on a 4-point scale: 0 (would never doze), 1 (slight chance of dozing), 2 (moderate chance), 3 (high chance). The total ESS score ranges from 0 to 24; a score of >10 indicates excessive daytime sleepiness (EDS), warranting clinical evaluation. A score of 11–15 indicates moderate EDS; 16–24 indicates severe EDS. The ESS correlates with objective sleep measures such as the Multiple Sleep Latency Test (MSLT) and is widely used in the diagnosis and monitoring of sleep disorders including obstructive sleep apnoea (OSA), narcolepsy, idiopathic hypersomnia, insufficient sleep syndrome, and the sleepiness-related effects of medications. It is the standard screening tool in sleep medicine clinics globally and is recommended by the American Academy of Sleep Medicine (AASM), the British Thoracic Society (BTS), and the European Respiratory Society (ERS) for OSA assessment and monitoring treatment response with CPAP therapy.
ESS Score = Sum of 8 situation scores (each 0–3); Total range 0–24; Interpretation: 0–10 = Normal range (no excessive daytime sleepiness); 11–12 = Mild EDS (marginal); 13–15 = Moderate EDS; 16–24 = Severe EDS; Each situation scored: 0 = would never doze; 1 = slight chance; 2 = moderate chance; 3 = high chance of dozing
- 1Provide the patient with the 8-situation ESS questionnaire and instruct them to rate the likelihood of dozing (not just feeling tired) in each situation based on their recent usual way of life.
- 2Situation 1: Sitting and reading (reading a book, newspaper, magazine, or document) — one of the most somnolent situations for people with EDS.
- 3Situation 2: Watching TV — sedentary, passive visual stimulus that readily induces drowsiness in the sleep-deprived.
- 4Situation 3: Sitting inactive in a public place (e.g., theatre, meeting, or lecture) — social inhibition usually suppresses dozing; high scores in this situation indicate severe EDS.
- 5Situation 4: As a passenger in a car for an hour without a break — monotonous passive travel is highly somnolent; scoring ≥2 in this situation carries road safety implications.
- 6Situation 5: Lying down to rest in the afternoon when circumstances permit — the most somnolent situation; high scores here are nearly universal in significant EDS.
- 7Situation 6: Sitting and talking to someone — a social interaction that suppresses sleep; dozing while talking to someone is a significant indicator of severe EDS.
- 8Situation 7: Sitting quietly after lunch without alcohol — post-prandial somnolence is physiologically normal; moderate scores common in mild EDS.
- 9Sum all 8 situation scores to get the total ESS score; interpret against clinical context; if ESS >10, initiate sleep disorder evaluation including history, BMI, STOP-BANG questionnaire for OSA, referral for polysomnography or home sleep testing as appropriate.
A score of 7 is within the population normal range; sleep quantity and quality appear adequate based on this assessment.
The majority of healthy adults without sleep disorders score 5–9 on the ESS; scores of 0 are uncommon and may indicate under-reporting.
An ESS of 16 combined with STOP-BANG ≥5 and obesity has a high positive predictive value for moderate-to-severe OSA.
In this clinical context, ESS confirms subjective EDS and supports urgent sleep study referral; OSA is the most likely diagnosis and CPAP treatment should be anticipated.
ESS improvement ≥3 points with CPAP is considered a clinically meaningful response; normalisation to <10 indicates optimal symptom control.
The ESS is the standard instrument for monitoring CPAP treatment response; a score returning to the normal range (≤10) while maintaining CPAP adherence ≥4h/night indicates effective OSA management.
ESS >15 in a young patient with the tetrad of EDS, cataplexy, sleep paralysis, and hypnagogic hallucinations is virtually diagnostic of narcolepsy type 1.
Narcolepsy produces the highest ESS scores in clinical practice (typically 15–24); confirmatory testing requires MSLT with ≥2 sleep-onset REM periods (SOREMPs) and/or CSF hypocretin-1 <110 pg/mL.
Small business owners use Epworth Sleepiness to evaluate pricing decisions, determine break-even points for new product lines, and calculate the margin impact of volume discounts offered to wholesale buyers and long-term contract customers.
Financial controllers at mid-size companies apply Epworth Sleepiness in monthly management reporting to track profitability trends, calculate variance against budget, and identify cost categories where operational efficiency improvements would have the greatest impact on bottom-line performance.
Startup founders use Epworth Sleepiness when building financial models for investor presentations, projecting runway based on current burn rate, and calculating the revenue growth rate needed to reach profitability before the next funding round.
Management consultants rely on Epworth Sleepiness to benchmark client performance against industry peers, quantify the financial impact of proposed operational improvements, and build business cases that justify capital investment decisions to executive leadership teams.
Extreme input values
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in epworth sleepiness calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Assumption violations
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in epworth sleepiness calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Rounding and precision effects
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in epworth sleepiness calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
ESS and pregnancy
Pregnancy is associated with increased subjective sleepiness, particularly in the first and third trimesters, and ESS scores are elevated on average compared to non-pregnant controls. OSA is more prevalent in pregnancy (particularly in women with obesity or pre-eclampsia) and carries risks for maternal and fetal outcomes. ESS screening in pregnancy clinics may identify women who warrant sleep study referral.
| ESS Score | Interpretation | Clinical Action |
|---|---|---|
| 0–10 | Normal — no excessive daytime sleepiness | Reassure; address sleep hygiene if borderline |
| 11–12 | Mild EDS — borderline | Clinical review; sleep history; lifestyle advice; repeat ESS |
| 13–15 | Moderate EDS | Sleep disorder evaluation; STOP-BANG; consider sleep study referral |
| 16–24 | Severe EDS | Urgent sleep study; driving safety assessment; restrict from safety-critical work if indicated |
| ≥16 + OSA confirmed | Severe OSA-related EDS | Urgent CPAP initiation; 4-week follow-up with repeat ESS |
| ESS reduction ≥3 on CPAP | Clinically meaningful treatment response | Continue CPAP; reassess annually |
What is excessive daytime sleepiness?
Excessive daytime sleepiness (EDS) is the tendency to fall asleep unintentionally or to fall asleep in inappropriate situations during normal waking hours. It is distinct from fatigue (physical or mental tiredness without an increased drive to sleep). EDS affects approximately 10–15% of the adult population and is most commonly caused by obstructive sleep apnoea, insufficient sleep, idiopathic hypersomnia, narcolepsy, medication side effects, or circadian rhythm disorders.
Is the ESS reliable across different languages and cultures?
The ESS has been translated and validated in over 50 languages with good reliability coefficients (Cronbach's alpha typically 0.73–0.88). However, cultural differences in sleepiness norms and reporting tendencies may affect population-level scores; normal reference ranges may need adjustment for different cultural contexts. ESS reliability is higher in clinical populations than in community surveys.
Can the ESS detect all causes of excessive daytime sleepiness?
The ESS measures subjective sleepiness but cannot identify its cause. It is a screening tool that indicates severity of EDS rather than diagnosis. An ESS >10 should trigger clinical evaluation including sleep history, medication review, questionnaires for OSA (STOP-BANG), and formal sleep studies (polysomnography or home sleep testing) to identify the underlying sleep disorder.
What ESS score is required for CPAP therapy funding in the UK?
NHS funding criteria for CPAP vary by region, but NICE CG173 (2014) recommends CPAP for adults with moderate-to-severe OSA (AHI ≥15/h) or for mild OSA (AHI 5–14/h) when ESS >9 or there are other relevant comorbidities (cardiovascular risk, occupational sleepiness). An ESS >10 combined with confirmed OSA on sleep study is the typical threshold for treatment initiation.
What is the MSLT and how does it relate to the ESS?
The Multiple Sleep Latency Test (MSLT) is an objective measurement of daytime sleepiness conducted in a sleep laboratory. The patient undergoes 4–5 nap opportunities across the day; sleep latency is measured for each nap. Mean sleep latency <8 minutes indicates abnormal sleepiness; <5 minutes is severe. The MSLT is the gold-standard objective measure for narcolepsy diagnosis (requires ≥2 SOREMPs) and correlates moderately with the ESS — they measure related but distinct aspects of sleepiness.
Does the ESS change with age?
ESS scores tend to be slightly lower in older adults compared to young and middle-aged adults — partly because older adults may have adapted their lifestyle to avoid somnolent situations or may have reduced awareness of sleepiness. Reference ranges for the ESS are based predominantly on adult populations aged 20–60; interpretation should be contextualised in elderly patients where lower absolute scores may still represent clinically meaningful sleepiness.
Can medications cause high ESS scores?
In the context of Epworth Sleepiness, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of business practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
Is the ESS suitable for use in children?
The ESS was developed for adults. A paediatric version (PDSS — Paediatric Daytime Sleepiness Scale) was developed for children. However, the ESS can be administered to adolescents (≥12 years) with good reliability. For younger children, parent-reported sleepiness measures (CSHQ — Children's Sleep Habits Questionnaire) are preferred. Sleepiness in school-age children is more commonly manifested as hyperactivity and inattention than as overt dozing.
Ammattilaisen vinkki
When a patient's CPAP compliance data shows good adherence (≥4h/night) but their ESS remains >10, do not assume treatment failure. Consider: (1) residual AHI on CPAP (leak, positional apnoeas); (2) a co-existing sleep disorder (narcolepsy, idiopathic hypersomnia, restless legs, periodic limb movement disorder); (3) medications causing EDS; (4) comorbid depression. A repeat polysomnography with CPAP is warranted.
Tiesitkö?
Dr Murray Johns named the Epworth Sleepiness Scale after the Epworth Hospital in Melbourne where he worked — not a historical person called Epworth. In 1991, when the scale was published, Johns' innovative idea of asking about situational dozing rather than just global tiredness was considered novel. The scale is now administered approximately 10 million times annually worldwide in sleep clinics and research studies.
Viitteet
- ›Johns MW — A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale (Sleep, 1991)
- ›Epworth Sleepiness Scale — Dr Murray Johns
- ›NICE CG173 — Continuous positive airways pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome (2014)
- ›AASM — Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea (2017)
- ›BTS Guideline — Sleep Apnoea and Hypopnoea Syndrome in Adults (2019)